The Onsemble Community Forum is your central hub to connect, collaborate, and grow alongside a network of clinical research professionals who rely on Advarra's suite of technology solutions. Built for research teams across academic medical centers, cancer centers, health systems, and other leading institutions, the forum provides a collaborative environment where users and Advarra experts engage in meaningful, product-focused discussions. Whether you're troubleshooting, sharing insights, or exploring best practices, the forum is designed to foster knowledge exchange and strengthen research operations. Within the forum, you’ll have access to product documentation and updates, on-demand webinars, detailed release notes, as well as information about upcoming events, collaboration calls, and live sessions. By joining the community, you can stay informed, share your expertise, and collaborate with peers who are advancing clinical research every day.
Daniel Eisenman, James Riddle, and Stephanie Pyle from Advarra all co-authored the published article, “Guidelines needed for the use of The post Guidelines needed for the use of AI in the preparation or review of IRB, IBC,and IACUC applications appeared first on Advarra.
Beyond the Breakthrough explores the challenges of CAR-T oncology trials, from complex logistics and safety risks to the critical role of cross-disciplinary coordination in delivering personalized cancer therapies. The post Beyond the Breakthrough: Navigating the realities of CAR-T cell oncology trials appeared first on Advarra.
Advarra has launched the Council for Responsible AI in Clinical Trials to ensure the ethical use of AI in clinical The post Navigating AI in Clinical Trials: Insights from Advarra’s Laura Russell appeared first on Advarra.
You can’t throw a rock in clinical research right now without hitting someone pitching some new AI-enabled app, solution, process The post Clinical Trials Get A Council For AI Oversight appeared first on Advarra.
Ophthalmology is quietly becoming gene therapy’s next big frontier. Here’s how the science, the patients, and the regulations are aligning. The post Gene Therapy Successes in Ophthalmology appeared first on Advarra.
Stuart Cotter dives in how today’s single sign-on reduces site burden and spearheads clinical system interoperability. The post The Latest Advancements in Single Sign-On Technology appeared first on Advarra.
Advarra’s Elisa Cascade joins other industry leaders, SCRS’ Jimmy Bechtel, Advarra’s Elisa Cascade, Tufts Center for the Study of Drug The post The “One-and-Done” PI & Measuring the Current Site Landscape appeared first on Advarra.
Christine Senn digs into the results of Advarra’s Site-Sponsor-CRO Collaboration survey to reveal some new trends to expect in the The post Clinical Research Trends to Expect in 2025: More Complex, Less Connected appeared first on Advarra.
Advarra deep-dives into special considerations needed for high-quality and sensitive pediatric oncology trial IRB reviews. The post A balancing act: Innovating IRBs for the future of pediatric oncology research appeared first on Advarra.
Advarra’s Christine Senn discusses compelling data from a recent site feasibility survey, the opportunity for CROs, and potential impact on The post The Broken Site Feasibility Process – Could CROs Be the Fixers? appeared first on Advarra.
For Jani Viox, clinical research is more than a profession—it’s personal. As a senior coordinator of client services at Advarra, Jani […] The post Q&A with Advarra’s Senior Coordinator of Client Services Jani Viox appeared first on Advarra.
Clinical trial study design forms the foundation of trial success. The decisions teams make at the design stage shape how […] The post How Smarter Clinical Trial Study Design Decisions Set Studies Up for Faster Startup and Fewer Amendments appeared first on Advarra.
Fueled by automation to remove one of the biggest barriers to adoption Increasingly, research sites are not just asking how […] The post Why Research Sites Are Switching to Connected eISF and CTMS appeared first on Advarra.
AI is becoming a routine part of how research proposals are prepared and reviewed, from drafting applications to supporting administrative […] The post New Paper Makes the Case for AI-Specific Guidance in Research Oversight appeared first on Advarra.
Traditional clinical trial designs often delay progress due to rigid protocols and frequent amendments. Adaptive and platform trial models introduce flexibility and shared infrastructure, reducing startup delays, cutting costs, and enabling sponsors to conduct faster, more efficient research. The post Reducing Startup Delays in Oncology Clinical Trials Through Consistent IRB Processes appeared first on Advarra.
Traditional clinical trial designs often delay progress due to rigid protocols and frequent amendments. Adaptive and platform trial models introduce flexibility and shared infrastructure, reducing startup delays, cutting costs, and enabling sponsors to conduct faster, more efficient research. The post What Are the Different Types of Study Designs? appeared first on Advarra.
For nearly a decade, Francine Lopez has helped clinical research move from idea to impact. From her early days at […] The post Q&A with Senior Manager of Client Services Francine Lopez appeared first on Advarra.
Oncology research continues to push scientific boundaries, from biomarker-driven therapies to increasingly personalized treatment strategies. Operationally, however, many oncology trials […] The post Rethinking Oncology Trial Design: Turning Insights from Data and Experience into More Feasible Studies appeared first on Advarra.
Traditional clinical trial designs often delay progress due to rigid protocols and frequent amendments. Adaptive and platform trial models introduce flexibility and shared infrastructure, reducing startup delays, cutting costs, and enabling sponsors to conduct faster, more efficient research. The post Insights on the FDA’s ELSA AI And What Changes Next appeared first on Advarra.
Traditional clinical trial designs often delay progress due to rigid protocols and frequent amendments. Adaptive and platform trial models introduce flexibility and shared infrastructure, reducing startup delays, cutting costs, and enabling sponsors to conduct faster, more efficient research. The post Preparing for Elsa: What Sponsors, Sites, and CROs Need to Know About the FDA’s New AI Era appeared first on Advarra.
It looks like you're new here. Sign in or register to get started.